{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:14:00Z","timestamp":1791753240123,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T00:00:00Z","timestamp":1317168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapy of Hodgkin lymphoma (HL) is designed to prolong survival and minimize toxicity. A total of 124 patients with newly diagnosed HL and adverse prognostic factors were prospectively studied between July, 1999 and August, 2005. Patients with early unfavorable and advanced disease were eligible for the study. Patients were assigned to therapy based on international prognostic score (IPS). Those with IPS \u2265 3 received three cycles of escalated BEACOPP (EB). All others received two cycles of standard BEACOPP (SB). Subsequent therapy was prospectively assigned according to early interim GA<jats:sup>67<\/jats:sup> or positron emission tomography (PET)\/computerized tomography (CT). Four cycles of EB or SB were administered following a positive or negative scan, respectively. Complete remission rate, 10\u2010year progression free (PFS), and overall survival (OS) were 97, 87, and 88%, respectively, at a median follow\u2010up of 89 months (5\u2013144). PFS and OS were similar in both groups. Fertility status was assessed in 38 females aged &lt;40 years; 94% of females younger than 40 years preserved their cyclic ovarian function. Nineteen conceived during follow\u2010up for 30 pregnancies, delivering 24 babies. Deliveries were reported up to 7 years from diagnosis. Predictive value of negative interim Ga<jats:sup>67<\/jats:sup> or PET\/CT was 87 and 93%, respectively. Six cycles of tailored BEACOPP, for patients with adverse prognostic factors, provide encouraging long\u2010term PFS and OS, and fertility is preserved in most females. Am. J. Hematol. 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.22187","type":"journal-article","created":{"date-parts":[[2011,9,12]],"date-time":"2011-09-12T17:13:02Z","timestamp":1315847582000},"page":"32-36","source":"Crossref","is-referenced-by-count":27,"title":["A 10\u2010year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved"],"prefix":"10.1002","volume":"87","author":[{"given":"Eldad J.","family":"Dann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bar\u2010Shalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menachem","family":"Ben\u2010Shachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Libster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gaitini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.160"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq066"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.138"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019901"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022473"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.086"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"307a","DOI":"10.1182\/blood.V104.11.307.307","article-title":"BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9\u2010 and HD12\u2010trials of the German Hodgkin Study Group (GHSG)","volume":"104","author":"Diehl V","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08485.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"2809a","DOI":"10.1182\/blood.V116.21.2809.2809","article-title":"Tailored therapy in hodgkin lymphoma, based on predefined risk factors and early interim PET\/CT, can lead to modification and safe reduction in therapy: Results of 134 patients on the Israel National Hodgkin Study","volume":"116","author":"Dann EJ","year":"2010","journal-title":"Blood"},{"key":"e_1_2_7_17_2","unstructured":"Cancer Research UK. Fludeoxyglucose F 18\u2010PET\/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II stage III or stage IV Hodgkin lymphoma. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT00678327(Accessed on August 31 2011)."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.210.2.r99fe07487"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi200"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2252"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2272020195"},{"key":"e_1_2_7_22_2","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease","volume":"91","author":"Gallamini A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.016105"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp271"},{"key":"e_1_2_7_26_2","first-page":"S18","article-title":"Early interim FDG\u2010PET during intensified BEACOPP for advanced\u2010stage Hodgkin disease shows a lower positive predictive value than during ABVD","volume":"95","author":"Fiore F","year":"2010","journal-title":"Haematologica"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1490-5"},{"key":"e_1_2_7_28_2","first-page":"166a","article-title":"Gonadal function in women after treatment of early unfavourable Hodgkin lymphoma (HL). First results of the fertility research project within the 5th trial generation, German Hodgkin Study Group (GHSG)","volume":"22","author":"Behringer K","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_7_29_2","unstructured":"Gallamini.PET\u2010response adapted clinical trials in lymphoma. Hematol Educ (The education program of the annual congress of the European Hematology Association)2010;4:204\u2013210."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.22187","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.22187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:55:46Z","timestamp":1698785746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.22187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/ajh.22187"],"URL":"https:\/\/doi.org\/10.1002\/ajh.22187","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,28]]}}}